ClinicalTrials.gg
CompletedNCT03399084Updated May 30, 2019

A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia

A Phase 1 interventional study of Ferric carboxymaltose in Iron Deficiency Anemia, sponsored by Sandoz. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-30.

Sponsored by Sandoz (formerly part of Novartis) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jan 2019, 7 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
34th of 57
71 · median 100
Started
2017
with 8 others
Phase 1
Only one
of the 57
Registered
27th of 57
by date

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 34th largest by enrollment, is one of 9 that started in 2017, is the only one in phase 1, and was the 27th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

This study will evaluate bioequivalence of two formulations of Ferric Carboxymaltose as measured by serum total iron, in adult patients with iron deficiency anemia.

03

Conditions studied

  • Iron Deficiency Anemia

Keywords

  • Ferric carboxymaltose
  • Anemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients at least 18 - 65 years of age;
  • Patients with a (BMI) between 18.5 - 35 and with a body weight of ≥50 kg - ≤130 kg;

Exclusion criteria

Exclusion Criteria:

  • Patients with known to ferric carboxymaltose, , or similar product
  • Patients with chronic kidney disease who are on dialysis of any kind.
  • If female, is pregnant or nursing.
  • Patients with blood loss leading to hemodynamic instability
  • Patients with recent parenteral iron within 3 months prior to screening.

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Ferric carboxymaltose (test)

    Patients will receive a single dose of Ferric carboxymaltose

    Drug: Ferric carboxymaltose

  • Active comparator
    Ferric carboxymaltose (reference)

    Patients will receive a single dose of Ferric carboxymaltose

    Drug: Ferric carboxymaltose

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence assessed by maximum serum concentration (Cmax)of serum total iron.

    Measured by Cmax - The maximum plasma concentration of iron

    Time frame: Up to 7 days

  2. Bioequivalence assessed by area under the serum concentration-time curve (AUC) of serum total iron.

    Plasma Pharmacokinetics (PK) of study medication: Area Under the Plasma Concentration-time Curve (AUC)

    Time frame: Up to 7 Days

Secondary outcomes

  1. Maximum serum concentration (Cmax) of serum transferrin-bound iron.

    Plasma Pharmacokinetics (PK): The maximum plasma concentration

    Time frame: Up to 7 days

  2. Time of Cmax (Tmax) of serum total iron and transferrin-bound iron

    Plasma Pharmacokinetics (PK): Time of Cmax (Tmax)

    Time frame: Up to 7 Days

  3. Area under the serum concentration-time curve (AUC) of serum transferrin-bound iron

    Plasma Pharmacokinetics (PK): area under the serum concentration-time curve (AUC)

    Time frame: Up to 7 Days

  4. Apparent terminal rate constant of serum total iron and transferrin-bound iron

    Plasma Pharmacokinetics (PK): Apparent terminal rate constant

    Time frame: Up to 7 Days

  5. Apparent terminal half-life of serum total iron and transferrin-bound iron

    Plasma Pharmacokinetics (PK): Apparent terminal half-life

    Time frame: Up to 7 Days

  6. Systemic clearance (CL) of serum total iron and transferrin-bound iron after intravenous dosing

    Plasma Pharmacokinetics (PK): Systemic clearance (CL)

    Time frame: Up to 7 Days

  7. Volume of distribution at steady state of serum total iron and transferrin-bound iron following intravenous dosing

    Plasma Pharmacokinetics (PK): Volume of distribution at steady state Plasma Pharmacokinetics (PK): Volume of distribution at steady state (Vss)

    Time frame: Up to 7 Days

  8. Number of patients with adverse events as a measure of safety and tolerability

    Time frame: Up to 7 days

07

Study locations

1 site
  • Sandoz Investigative Site
    Miami, Florida 33143, United States
08

References and documents

Individual participant data

Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Jan 2019, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2017
First posted
Jan 16, 2018
StartActual
Nov 29, 2017
Primary completionActual
Jan 15, 2019
CompletionActual
Jan 15, 2019
Last update
May 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03399084
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Jan 16, 2018
Start date
Nov 29, 2017
Primary completion
Jan 15, 2019
Completion
Jan 15, 2019
Last update
May 30, 2019

Study contacts

Sandoz Sandoz
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion